RESEARCH 研究の報告

2025.4.23

Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.

著者 Shiono A, Imai H, Endo S, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Mol Clin Oncol. 2025 Apr 23;22(6):58. doi: 10.3892/mco.2025.2853. eCollection 2025 Jun.

PMID: 40322546

2025.4.1

A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.

著者 Mouri A, Imai H, Endo S, Nakagawa J, Tsukamoto K, Kurata Y, Yamaguchi O, Masaki K, Hashimoto K, Shiono A, Miura Y, Kobayashi K, Kaira K, Kagamu H.

Cancer Med. 2025 Apr;14(8):e70741. doi: 10.1002/cam4.70741.

PMID: 40249663

2025.2.1

Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer.

著者 Matsukida A, Imai H, Shiono A, Ryuno Y, Hashimoto K, Miura YU, Endo S, Okazaki S, Yamaguchi OU, Mouri A, Abe T, Kaira K, Kobayashi K, Kato S, Kagamu H.

Anticancer Res. 2025 Feb;45(2):733-741. doi: 10.21873/anticanres.17461.

PMID: 39890195

2025.1.23

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.

著者 Endo S, Imai H, Mouri A, Tsukamoto K, Masaki K, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Nakagawa J, Kaira K, Kobayashi K, Kagamu H.

J Cancer Res Clin Oncol. 2025 Jan 23;151(1):43. doi: 10.1007/s00432-025-06089-x.

PMID: 39843575

2024.11.18

Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer.

著者 Hashimoto K, Kaira K, Imai H, Yamaguchi O, Mouri A, Shiono A, Miura Y, Kobayashi K, Kagamu H, Kuji I.

Cancer Imaging. 2024 Nov 18;24(1):157. doi: 10.1186/s40644-024-00800-w.

PMID: 39558409

2024.9.1

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.

著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.

PMID: 39287161

2024.8.5

The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.

著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.

Oncology. 2025;103(2):83-93. doi: 10.1159/000540651. Epub 2024 Aug 5.

PMID: 39102792

2024.9.1

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from two institutions and review of the literature.

著者 Shiono A, Imai H, Endo S, Katayama K, Sato H, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Kobayashi K, Minato K, Kato S, Kagamu H.

Radiol Oncol. 2024 Sep 15;58(3):432-443. doi: 10.2478/raon-2024-0054. eCollection 2024 Sep 1.

PMID: 39287161 Free PMC article. Review.

2024.8.5

The Glasgow Prognostic Score as a Predictor of Survival after Chemoradiotherapy for Limited-Disease Small Cell Lung Cancer.

著者 Endo S, Imai H, Shiono A, Hashimoto K, Miura Y, Okazaki S, Abe T, Mouri A, Kaira K, Masubuchi K, Masubuchi T, Kobayashi K, Minato K, Kato S, Kagamu H.

Oncology. 2024 Aug 5:1-11. doi: 10.1159/000540651. Online ahead of print.

PMID: 39102792

2024.5.20

D-dimer cut-off value for predicting venous thromboembolism at the initial diagnosis in Japanese patients with advanced lung cancer.

著者 Kawakado K, Tsubata Y, Hotta T, Yamasaki M, Ishikawa N, Masuda T, Kubota T, Kobayashi K, Isobe T.

Jpn J Clin Oncol. 2024 May 20:hyae064. doi: 10.1093/jjco/hyae064. Epub ahead of print.

PMID: 38769814.

2024.4.1

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.

著者 Tsukita Y, Tozuka T, Kushiro K, Hosokawa S, Sumi T, Uematsu M, Honjo O, Yamaguchi O, Asao T, Sugisaka J, Saito G, Shiihara J, Morita R, Katakura S, Yasuda T, Hisakane K, Miyauchi E, Morita S, Kobayashi K, Asahina H.

JAMA Oncol. 2024 Apr 1;10(4):439-447. doi: 10.1001/jamaoncol.2023.6277.

PMID: 38451530; PMCID: PMC10921348.

2024.2.20

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060.

著者 Tozuka T, Minegishi Y, Yamaguchi O, Watanabe K, Toi Y, Saito R, Nagai Y, Tamura Y, Shoji T, Odagiri H, Ebi N, Sakai K, Kanaji N, Izumi M, Soda S, Watanabe S, Morita S, Kobayashi K, Seike M.

JTO Clin Res Rep. 2024 Feb 20;5(4):100655. doi: 10.1016/j.jtocrr.2024.100655.

PMID: 38706978; PMCID: PMC11069015.